AJP - Lung Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Lung Cell Mol Physiol 295: L400-L411, 2008. First published July 18, 2008; doi:10.1152/ajplung.00041.2008
1040-0605/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/3/L400    most recent
00041.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Card, J. W.
Right arrow Articles by Nestmann, E. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Card, J. W.
Right arrow Articles by Nestmann, E. R.

REVIEW

Pulmonary applications and toxicity of engineered nanoparticles

Jeffrey W. Card,1 Darryl C. Zeldin,2 James C. Bonner,3 and Earle R. Nestmann1

1Cantox Health Sciences International, Mississauga, Ontario, Canada; 2Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, and 3Department of Environmental and Molecular Toxicology, North Carolina State University, Raleigh, North Carolina

ABSTRACT

Because of their unique physicochemical properties, engineered nanoparticles have the potential to significantly impact respiratory research and medicine by means of improving imaging capability and drug delivery, among other applications. These same properties, however, present potential safety concerns, and there is accumulating evidence to suggest that nanoparticles may exert adverse effects on pulmonary structure and function. The respiratory system is susceptible to injury resulting from inhalation of gases, aerosols, and particles, and also from systemic delivery of drugs, chemicals, and other compounds to the lungs via direct cardiac output to the pulmonary arteries. As such, it is a prime target for the possible toxic effects of engineered nanoparticles. The purpose of this article is to provide an overview of the potential usefulness of nanoparticles and nanotechnology in respiratory research and medicine and to highlight important issues and recent data pertaining to nanoparticle-related pulmonary toxicity.

nanotechnology; nanomaterials; respiratory system; lung


Address for reprint requests and other correspondence: J. W. Card, Cantox Health Sciences International, 2233 Argentia Rd., Suite 308, Mississauga, Ontario, Canada L5N 2X7 (e-mail: jcard{at}cantox.com)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.